Apremilast
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Apremilast
Apremilast: Known uses and market status in Canada
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Apremilast, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 4 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 10 of 11; dormant: 1) |
| Number of DINs | 11 (marketed: 10) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| behcet syndrome | licence in another country |
| oral ulcer | licence in another country |
| psoriasis | licence in another country |
| psoriatic arthritis | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02434334 | OTEZLA | Valid | |
| 02521733 | PMS-APREMILAST | Valid | |
| 02528959 | JAMP APREMILAST | Valid | |
| 02529092 | SANDOZ APREMILAST | Valid | |
| 02538180 | APO-APREMILAST | Valid | |
| 02434318 | OTEZLA | Valid | |
| 02524104 | AURO-APREMILAST | Valid | |
| 02529084 | SANDOZ APREMILAST | Valid | |
| 02528967 | JAMP APREMILAST | Valid | |
| 02524120 | AURO-APREMILAST | Valid | |
| 02518910 | GLN-APREMILAST | DORMANT |
Safety Considerations
Drug Interactions: The interaction screen identified 75 potential interactions. The first 20 listed include:
- Major: lumacaftor, fosphenytoin, apalutamide
- Moderate: dexamethasone, troglitazone, deferasirox, fostamatinib, betrixaban, lusutrombopag, griseofulvin, elagolix, somatrem, somatotropin, abametapir (topical), amobarbital, aminoglutethimide, bexarotene, binimetinib, bosentan
- Minor: armodafinil
Several of the major and moderate interactions involve enzyme inducers. The full list of 75 should be reviewed in the package insert.
Please refer to the package insert for other safety information, including warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.